Perspective Therapeutics, Inc.CATXEarnings & Financial Report

NYSE · pharmaceutical industry

Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.

Revenue

$-3.8M

Gross Profit

$-39.0K

Operating Profit

$-7.8M

Net Profit

$-24.7M

Gross Margin

1.0%

Operating Margin

205.2%

Net Margin

648.5%

YoY Growth

N/A

EPS

$-0.97

Perspective Therapeutics, Inc. Q4 2023 Financial Summary

Perspective Therapeutics, Inc. reported revenue of $-3.8M for Q4 2023, with a net profit of $-24.7M (648.5% margin). Cost of goods sold was $-3.8M, operating expenses totaled $7.8M.

Key Financial Metrics

Total Revenue	$-3.8M
Net Profit	$-24.7M
Gross Margin	1.0%
Operating Margin	205.2%
Report Period	Q4 2023

Perspective Therapeutics, Inc. Annual Revenue by Year

Perspective Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $2.5M).

Year	Annual Revenue
2023	$2.5M

Income Statement

	Q1 2022	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023
Revenue	$2.9M	$2.5M	$1.7M	$2.1M	$2.1M	$2.2M	$-3.8M
YoY Growth	11.9%	-7.6%	-33.0%	-29.1%	-16.6%	27.3%	N/A

Balance Sheet

	Q1 2022	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023
Assets	$66.1M	$64.4M	$62.5M	$127.6M	$120.1M	$110.5M	$97.9M
Liabilities	$2.9M	$3.2M	$4.8M	$9.6M	$11.5M	$11.7M	$22.7M
Equity	$63.2M	$61.3M	$57.7M	$118.0M	$108.7M	$98.8M	$75.2M